Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02537067
Other study ID # 04CON
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received August 13, 2015
Last updated August 28, 2015
Start date January 2010
Est. completion date December 2015

Study information

Verified date August 2015
Source Sewon Cellontech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry of Food and Drug SafetyKorea: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of Chondron (Autologus Chondrocyte) in patients with cartilage defects in their ankle for 18 months


Description:

This is an open label trial, involving a total of 28 subjects. Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant. During the trial period, subjects must follow the instructions given by principal investigator. Subjects will make 6* hospital visits on a regular basis inclusive of hospitalization. During these visits subjects will be examined. For the evaluation of safety and efficacy of CHONDRON, examination with doctors, x-ray, MRI tests and arthroscopy will be performed. *If tissue samples can be collected at screening visit, there will be only 5 visits.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 28
Est. completion date December 2015
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 15 Years to 65 Years
Eligibility Inclusion Criteria:

- 1. Adult men and women over 15 and less than 65 years of age 2. Applicable to patients who have a partial cartilage defect in their ankle based on an MRI (defect size: for a single lesion, less than 15 cm2; and for multiple lesions, less than 20 cm2) 3. Patients with ankle-tibia malalignment of the ankle joint, unstable ankle ligaments, bone defects at the cartilage defect area or patients who received correction in advance 4. Patients which surrounding cartilage are normal 5.Patients with a Grade III or IV cartilage defect size on the ICRS (International Cartilage Repair Society) 6. Patients who agreed to clinical trial participation voluntarily or by the will of the person in parental authority, and signed the written consent form

Exclusion Criteria:

- 1. Patients hypersensitive to bovine protein 2. Patients hypersensitive to gentamicin antibiotics 3. Patients with inflammatory arthritis such as rheumatoid arthritis, gout arthritis 4. Patients with arthritis related to autoimmune disease 5. Pregnant, breast-feeding patients or those who have a possibility of pregnancy 6. Patients with accompanying diseases other than articular cartilage defects, including tumors 7. Patients who have a history of receiving radiotherapy, chemotherapy in the last 2 years 8. Patients with diabetes (however, patients whose blood sugar test results are normal and do not have any complication of diabetes, when a written opinion that CHONDRON administration is possible is appended by a doctor are excluded) 9. Patients who are administering antibiotics and antimicrobial agents due to infection 10. Patients who receive steroid hormone therapy 11. Patients with psychiatric disorder and those who are considered to be inappropriate for this trial by the judgment of the clinical trial manager

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
CHONDRON
Harvesting of ankle or knee cartilage The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.

Locations

Country Name City State
Korea, Republic of Myongji Hospital Goyang Gyeonggi
Korea, Republic of Eulji General Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Sewon Cellontech Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Grade change of ICRS(International Cartilage Repair Society) by arthroscopy The change of ICRS grade of the affected ankle shall be assessed at 12 months after the surgery. The results on the surgery date shall be considered the baseline data and shall be compared with those at 12 months after the surgery based on arthroscopy. For the final efficacy evaluation, the percentage of the patients (success rate) who showed Grade III or IV ICRS before the surgery and improved to Grade 0 or I after the surgery will be calculated. 12 months after the surgery No
Secondary Score change of AOFAS(American orthopedic foot & ankle society) Score The improvements in the AOFAS in the affected ankle at baseline and six, 12 and 18 months after the surgery will be compared. The final efficacy evaluation shall be done by calculating the difference between the AOFAS at the baseline and that 18 months after the surgery. baseline and six, 12 and 18 months after the surgery No
Secondary Hannover Score The improvements in the Hannover score in the affected ankle at baseline and six, 12 and 18 months after the surgery will be compared. The final efficacy evaluation shall be done by calculating the difference between the Hannover score at the baseline and that 18 months after the surgery. baseline and six, 12 and 18 months after the surgery No
Secondary Score change of Evaluation by physician in charge The improvement will be evaluated by the physician using a five-level scale six, 12 and 18 months after the Chondron grafting. six, 12 and 18 months after the surgery No
Secondary Score change of 100mmVAS(visual analogue scale) The improvements of pain in the 100mmVAS in the affected ankle at baseline and six, 12 and 18 months after the surgery will be compared. The final efficacy evaluation shall be done by calculating the difference between the 100mmVAS at the baseline and that 18 months after the surgery. baseline and six, 12 and 18 months after the surgery No
Secondary Comparing MRI results The morphological improvement from MRI image of the affected ankle will be assessed at 18 months after the surgery from those at baseline. For MRI image at baseline, the MRI should be performed within two weeks from the Chondron grafting for the efficacy evaluation. baseline and 18 months after the surgery No
See also
  Status Clinical Trial Phase
Completed NCT01473199 - BioPoly RS Knee Registry Study for Cartilage Defect Replacement N/A
Active, not recruiting NCT01670617 - DeNovo NT Natural Tissue Graft Stratified Knee Study N/A
Active, not recruiting NCT01347892 - DeNovo NT Ankle LDC Study N/A
Completed NCT02203071 - Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee
Completed NCT01626677 - Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect Phase 3
Active, not recruiting NCT02855073 - Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects Phase 2
Completed NCT01290991 - A Study to Evaluate the Safety of Augmentâ„¢ Bone Graft N/A
Terminated NCT01400607 - Neocartilage Implant to Treat Cartilage Lesions of the Knee Phase 3
Terminated NCT00881023 - Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration N/A
Terminated NCT02542566 - Protected Versus Early Weight Bearing Post Microfracture Surgery N/A
Completed NCT02696876 - Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair N/A
Active, not recruiting NCT02524509 - the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee Phase 4
Recruiting NCT02519881 - the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Ankle Phase 4
Active, not recruiting NCT02539030 - Comparison of Efficacy and Safety of Microfracture and Modified Microfracture Phase 4
Active, not recruiting NCT02659215 - HyaloFAST Trial for Repair of Articular Cartilage in the Knee N/A
Terminated NCT01410136 - Chondrofix Osteochondral Allograft Prospective Study N/A
Active, not recruiting NCT00885729 - Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects Phase 1
Terminated NCT01246635 - Smith & Nephew's European Trufit Study N/A